Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of your #1 sort of juice - 2Genome study reveals milestone in history of cat domestication
- 3NASA Perseverance rover sees megaripples on Mars | Space photo of the day for Jan. 7, 2026.
- 4Vote In favor of Your Favored Language Interpretation Administration
- 5Find the Abilities Required for Advanced Advertising Position
- The Way to Recuperation: Defeating Dependence
- Experience Unrivaled Sound: Top Speakers You Really want to Hear
- Best Getaway destination: Ocean side, Mountain, or City
- World leaders, rights groups react to COP30 climate deal
- Living in the dark: Gaza’s struggle for electricity
- Polls open in tense Uganda election amid widespread delays
- First SpaceX booster for upgraded Starship fails during test in Texas
- Munich Security Conference chief defends inviting AfD lawmakers
- Are protests pushing Iran's Islamic regime toward a tipping point?
